Compare ADPT & TFSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | TFSL |
|---|---|---|
| Founded | 2009 | 1938 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.8B |
| IPO Year | 2019 | 2006 |
| Metric | ADPT | TFSL |
|---|---|---|
| Price | $25.90 | $16.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $28.31 | $18.25 |
| AVG Volume (30 Days) | ★ 2.3M | 601.6K |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 7.88% |
| EPS Growth | ★ 63.89 | 14.29 |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $5.94 | $8.17 |
| Revenue Next Year | $22.42 | $7.60 |
| P/E Ratio | ★ N/A | $59.70 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $12.00 | $12.54 |
| 52 Week High | $30.74 | $19.49 |
| Indicator | ADPT | TFSL |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 37.80 |
| Support Level | $23.73 | $16.11 |
| Resistance Level | $26.51 | $17.00 |
| Average True Range (ATR) | 1.43 | 0.30 |
| MACD | -0.37 | -0.01 |
| Stochastic Oscillator | 12.46 | 28.90 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.